Agitation,Psychomotor
2
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
0
0
1
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
BioXcel TherapeuticsCT - New Haven
2 programs1
1
BXCL501Phase 31 trial
Sublingual film containing DexmedetomidinePhase 1/21 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
BioXcel TherapeuticsBXCL501
BioXcel TherapeuticsSublingual film containing Dexmedetomidine
Clinical Trials (2)
Total enrollment: 552 patients across 2 trials
Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III)
Start: Nov 2022Est. completion: Aug 2025452 patients
Phase 3Completed
Sub-Lingual Dexmedetomidine in Agitation Associated With Dementia
Start: Dec 2019Est. completion: Jan 2022100 patients
Phase 1/2Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs, potential near-term approvals
1 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.